Co-Diagnostics, Inc. (NASDAQ:CODX – Get Free Report) saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 309,900 shares, a decrease of 12.3% from the July 15th total of 353,200 shares. Based on an average daily volume of 130,300 shares, the days-to-cover ratio is currently 2.4 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lowered their target price on shares of Co-Diagnostics from $2.00 to $1.50 and set a “neutral” rating on the stock in a research note on Monday, August 12th.
Check Out Our Latest Research Report on Co-Diagnostics
Co-Diagnostics Stock Up 26.0 %
Hedge Funds Weigh In On Co-Diagnostics
An institutional investor recently raised its position in Co-Diagnostics stock. SMI Advisory Services LLC lifted its holdings in Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) by 117.7% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 38,089 shares of the company’s stock after purchasing an additional 20,590 shares during the period. SMI Advisory Services LLC owned about 0.12% of Co-Diagnostics worth $43,000 at the end of the most recent reporting period. Institutional investors own 14.99% of the company’s stock.
Co-Diagnostics Company Profile
Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.
Featured Stories
- Five stocks we like better than Co-Diagnostics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- The Role Economic Reports Play in a Successful Investment Strategy
- 2 Option Strategies to Maximize Profits in a Bear Market
- What Makes a Stock a Good Dividend Stock?
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.